Version history

{
  "session_id": "sess_sda-2026-04-01-gap-auto-fd6b1635d9",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "agent_backend": "us.anthropic.claude-sonnet-4-20250514-v1:0",
  "action": "support",
  "content": "## CRITICAL FEASIBILITY ASSESSMENT\n\nI must agree with both the Theorist and Critic - **there is a fundamental impossibility in assessing neurodegeneration therapeutic hypotheses with the provided literature**. This is not merely a methodological concern but a basic scientific validity issue.\n\n## Primary Assessment: **CANNOT PROCEED WITH NEURODEGENERATION EVALUATION**\n\n### Evidence Gap Analysis\n\nThe literature provided consists entirely of research methodology papers:\n\n1. **PMID:30654913** - qPCR protocols (no therapeutic targets)\n2. **PMID:36909790** - Sample size calculations (statistical methodology)\n3. **PMID:29937585** - Qualitative research saturation (methodology)\n4. **PMID:24413767** - Phenomenological interviewing (methodology)\n5. **PMID:29185826** - Qualitative research design (methodology)\n\n**Zero papers address:**\n- Neurodegenerative disease mechanisms\n- Molecular targets (APOE, TREM2, α-synuclein, tau, etc.)\n- Existing therapeutics\n- Disease pathophysiology\n- Clinical outcomes\n\n### Practical Reality Check\n\n**For legitimate therapeutic hypothesis assessment, I require literature covering:**\n\n1. **Target Biology**: Papers on specific proteins/pathways implicated in neurodegeneration\n2. **Druggability**: Structure-activity relationships, binding pockets, chemical matter\n3. **Clinical Precedent**: Existing drugs, failed trials, lessons learned\n4. **Safety Profile**: Known toxicities, off-target effects\n5. **Competitive Intelligence**: Pipeline drugs, patent landscape\n\n## Alternative Feasible Assessment\n\nI can provide a meaningful evaluation if you want **methodological hypotheses** for improving neurodegeneration research quality:\n\n### Hypothesis A: \"Implementing standardized qPCR protocols improves biomarker reproducibility in AD studies\"\n\n**Feasibility: HIGH**\n- **Existing Tools**: PMID:30654913 provides validated protocols\n- **Cost**: $50K-100K for protocol standardization across sites\n- **Timeline**: 6-12 months implementation\n- **Evidence**: Figure from PMID:36909790 shows power analysis methods for such studies\n\n### Hypothesis B: \"Optimized sample sizes reduce false negatives in neurodegeneration clinical trials\"\n\n**Feasibility: HIGH**\n- **Methodology**: PMID:36909790 provides calculation frameworks\n- **Implementation Cost**: Minimal ($10K-25K for statistical consulting)\n- **Impact Potential**: Could prevent costly underpowered trials\n\n## Recommendation\n\n**Provide neurodegeneration-specific literature** including:\n- Recent papers on AD/PD mechanisms\n- Clinical trial outcomes in neurodegeneration\n- Molecular target validation studies\n- Biomarker development papers\n\nOR\n\n**Confirm you want methodological feasibility assessment** using the provided methodology papers.\n\n**Current Status: Cannot assess therapeutic hypotheses with 0% relevant disease literature.**\n\nWould you like me to search for recent neurodegeneration literature to enable proper therapeutic hypothesis evaluation?",
  "tokens_used": "735",
  "persona_id": "persona-domain_expert"
}